Single-center experience with implantable cardioverter-defibrillators in adults with complex congenital heart disease

Amber D. Khanna, Carole A. Warnes, Sabrina D. Phillips, Grace D Lin, Peter A. Brady

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Adults with congenital heart disease are at risk of lethal ventricular arrhythmias and are candidates for implantable cardiac defibrillator (ICD) therapy, yet implant risks, long-term outcomes, and rates of appropriate and inappropriate ICD therapies are not well characterized. We reviewed clinical, implantation, and follow-up data on all transvenous ICDs in adults with congenital heart disease at the Mayo Clinic from 1991 through 2008. Seventy-three adults with congenital heart disease received 85 ICDs. Implantation diagnoses included tetralogy of Fallot (44%) and congenitally corrected transposition of the great arteries (17%). Implantation indication was occurrence of sustained ventricular arrhythmias (secondary prevention) in 36% and prophylactic (primary prevention) in the remainder. There were no major implant-related complications. During follow-up (2.2 ± 2.8 years, range 0 to 15) 11 patients died and 4 patients received heart or heart/lung transplants. An appropriate shock for a ventricular arrhythmia was observed in 19% of patients and an inappropriate shock was observed in 15% of patients. Likelihood of an appropriate shock was associated with increased subpulmonic ventricular pressure. In conclusion, implantation of transvenous ICDs in adults with congenital heart disease is associated with a low risk of implant complications. In this high-risk adult population the rate of inappropriate ICD shocks is low, whereas the likelihood of appropriate therapy for potentially lethal ventricular arrhythmias is high. These data suggest overall benefit of ICD therapy in adults with congenital heart disease.

Original languageEnglish (US)
Pages (from-to)729-734
Number of pages6
JournalAmerican Journal of Cardiology
Volume108
Issue number5
DOIs
StatePublished - Sep 1 2011

Fingerprint

Implantable Defibrillators
Heart Diseases
Cardiac Arrhythmias
Shock
Tetralogy of Fallot
Ventricular Pressure
Primary Prevention
Therapeutics
Secondary Prevention
Transplants
Lung
Population

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Single-center experience with implantable cardioverter-defibrillators in adults with complex congenital heart disease. / Khanna, Amber D.; Warnes, Carole A.; Phillips, Sabrina D.; Lin, Grace D; Brady, Peter A.

In: American Journal of Cardiology, Vol. 108, No. 5, 01.09.2011, p. 729-734.

Research output: Contribution to journalArticle

Khanna, Amber D. ; Warnes, Carole A. ; Phillips, Sabrina D. ; Lin, Grace D ; Brady, Peter A. / Single-center experience with implantable cardioverter-defibrillators in adults with complex congenital heart disease. In: American Journal of Cardiology. 2011 ; Vol. 108, No. 5. pp. 729-734.
@article{ec47e675fcdd443785711af65e78cc5d,
title = "Single-center experience with implantable cardioverter-defibrillators in adults with complex congenital heart disease",
abstract = "Adults with congenital heart disease are at risk of lethal ventricular arrhythmias and are candidates for implantable cardiac defibrillator (ICD) therapy, yet implant risks, long-term outcomes, and rates of appropriate and inappropriate ICD therapies are not well characterized. We reviewed clinical, implantation, and follow-up data on all transvenous ICDs in adults with congenital heart disease at the Mayo Clinic from 1991 through 2008. Seventy-three adults with congenital heart disease received 85 ICDs. Implantation diagnoses included tetralogy of Fallot (44{\%}) and congenitally corrected transposition of the great arteries (17{\%}). Implantation indication was occurrence of sustained ventricular arrhythmias (secondary prevention) in 36{\%} and prophylactic (primary prevention) in the remainder. There were no major implant-related complications. During follow-up (2.2 ± 2.8 years, range 0 to 15) 11 patients died and 4 patients received heart or heart/lung transplants. An appropriate shock for a ventricular arrhythmia was observed in 19{\%} of patients and an inappropriate shock was observed in 15{\%} of patients. Likelihood of an appropriate shock was associated with increased subpulmonic ventricular pressure. In conclusion, implantation of transvenous ICDs in adults with congenital heart disease is associated with a low risk of implant complications. In this high-risk adult population the rate of inappropriate ICD shocks is low, whereas the likelihood of appropriate therapy for potentially lethal ventricular arrhythmias is high. These data suggest overall benefit of ICD therapy in adults with congenital heart disease.",
author = "Khanna, {Amber D.} and Warnes, {Carole A.} and Phillips, {Sabrina D.} and Lin, {Grace D} and Brady, {Peter A.}",
year = "2011",
month = "9",
day = "1",
doi = "10.1016/j.amjcard.2011.04.020",
language = "English (US)",
volume = "108",
pages = "729--734",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Single-center experience with implantable cardioverter-defibrillators in adults with complex congenital heart disease

AU - Khanna, Amber D.

AU - Warnes, Carole A.

AU - Phillips, Sabrina D.

AU - Lin, Grace D

AU - Brady, Peter A.

PY - 2011/9/1

Y1 - 2011/9/1

N2 - Adults with congenital heart disease are at risk of lethal ventricular arrhythmias and are candidates for implantable cardiac defibrillator (ICD) therapy, yet implant risks, long-term outcomes, and rates of appropriate and inappropriate ICD therapies are not well characterized. We reviewed clinical, implantation, and follow-up data on all transvenous ICDs in adults with congenital heart disease at the Mayo Clinic from 1991 through 2008. Seventy-three adults with congenital heart disease received 85 ICDs. Implantation diagnoses included tetralogy of Fallot (44%) and congenitally corrected transposition of the great arteries (17%). Implantation indication was occurrence of sustained ventricular arrhythmias (secondary prevention) in 36% and prophylactic (primary prevention) in the remainder. There were no major implant-related complications. During follow-up (2.2 ± 2.8 years, range 0 to 15) 11 patients died and 4 patients received heart or heart/lung transplants. An appropriate shock for a ventricular arrhythmia was observed in 19% of patients and an inappropriate shock was observed in 15% of patients. Likelihood of an appropriate shock was associated with increased subpulmonic ventricular pressure. In conclusion, implantation of transvenous ICDs in adults with congenital heart disease is associated with a low risk of implant complications. In this high-risk adult population the rate of inappropriate ICD shocks is low, whereas the likelihood of appropriate therapy for potentially lethal ventricular arrhythmias is high. These data suggest overall benefit of ICD therapy in adults with congenital heart disease.

AB - Adults with congenital heart disease are at risk of lethal ventricular arrhythmias and are candidates for implantable cardiac defibrillator (ICD) therapy, yet implant risks, long-term outcomes, and rates of appropriate and inappropriate ICD therapies are not well characterized. We reviewed clinical, implantation, and follow-up data on all transvenous ICDs in adults with congenital heart disease at the Mayo Clinic from 1991 through 2008. Seventy-three adults with congenital heart disease received 85 ICDs. Implantation diagnoses included tetralogy of Fallot (44%) and congenitally corrected transposition of the great arteries (17%). Implantation indication was occurrence of sustained ventricular arrhythmias (secondary prevention) in 36% and prophylactic (primary prevention) in the remainder. There were no major implant-related complications. During follow-up (2.2 ± 2.8 years, range 0 to 15) 11 patients died and 4 patients received heart or heart/lung transplants. An appropriate shock for a ventricular arrhythmia was observed in 19% of patients and an inappropriate shock was observed in 15% of patients. Likelihood of an appropriate shock was associated with increased subpulmonic ventricular pressure. In conclusion, implantation of transvenous ICDs in adults with congenital heart disease is associated with a low risk of implant complications. In this high-risk adult population the rate of inappropriate ICD shocks is low, whereas the likelihood of appropriate therapy for potentially lethal ventricular arrhythmias is high. These data suggest overall benefit of ICD therapy in adults with congenital heart disease.

UR - http://www.scopus.com/inward/record.url?scp=80051803254&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80051803254&partnerID=8YFLogxK

U2 - 10.1016/j.amjcard.2011.04.020

DO - 10.1016/j.amjcard.2011.04.020

M3 - Article

VL - 108

SP - 729

EP - 734

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 5

ER -